Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours

It hasn't been easy for biopharmaceutical firms to go public in the US during 2016, but as of the end of June the scrutiny seems to be paying off – at least for investors in half of this year's first-half initial public offerings.